Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT07039162 · RECRUITING

Trial details

NCT number: NCT07039162
Sponsor: Ming-Yu Lien
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer

Start date: 2025-09-26
Primary completion: 2028-12-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.